Company Analysis

ProKidney Corp. (PROK)

Nasdaq: PROK · Biological Products, (No Diagnostic Substances) · Winston-Salem, NC · filing with the SEC since 2021
Grade5.3
◀ Past 5.6● Present 3.6▶ Future 6.5
3 est.

The grade of ProKidney Corp.

Nine metrics read from its own filings, by tense
Headline grade
5.3/10
◀ Past5.625% of the headline
● Present3.635% of the headline
▶ Future6.540% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.6/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
2.0/10

Has it survived what it has been through?

3 warning events since 2021; the latest 2022-07-15.

weight 22% of this tense · 20th percentile among 159 sector filers · read for itself

From the record

ProKidney Corp.'s filings since 2021 show 3 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2022-07-12); a warning not to rely on past financial statements (8-K item 4.02, the latest 2021-11-16); an auditor change (8-K item 4.01, the latest 2022-07-15) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
7.1/10

What has it actually done, year after year?

4 filed years; profitable in 0 of 4.

weight 45% of this tense · 71st percentile among 102 sector filers · read for its customers

From the record

ProKidney Corp.'s 4 filed years say what it did: it rose in 1 of 1 years; it never fell from a peak; net income was positive in 0 of 4 of those years (its annual reports).

What it rests on

  • the share of years revenue rosetop 8% of its family
  • the share of filed years with a profitbottom 31% of its family
  • the deepest fall from a revenue peak0.0%top 9% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
5.8/10

How has it treated the people who own it?

SI estimate 5.8/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 107 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 107 members with one.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
family median, 107 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: ProKidney Corp.'s shareholder treatment is put at 5.8 of 10 with a confidence of 20 of 100, because fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 107 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.6/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

SI estimate
4.9/10

Is it financially healthy right now?

SI estimate 4.9/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 152 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate
Fewer than two of the four checks can be read, so the desk assumes the typical reading of its industry family, the median of 152 members with one.
What the record cannot read
Fewer than two of the four checks can be read.
How it was reasoned
family median, 152 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: ProKidney Corp.'s financial health is put at 4.9 of 10 with a confidence of 20 of 100, because fewer than two of the four checks can be read, so the desk assumes the typical reading of its industry family, the median of 152 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Industry position

as filed
1.3/10

How strong is its position in its industry?

bottom 13% of 102 in its family; net margin -16977.8%.

weight 22% of this tense · 13th percentile among 102 sector filers · read for its customers

From the record

ProKidney Corp.'s standing among 102 graded names in its industry family: revenue of $893 thousand in fiscal 2025 ranks in the bottom 18% by size; a net margin of -16977.8% ranks in the bottom 9% (its annual reports).

What it rests on

  • revenue against the family$893,000bottom 18% of its family
  • net margin-16977.8%bottom 9% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
3.5/10

What are the people in charge doing?

bottom 35% of 110 in its family for leadership; chief executive since 2023.

weight 33% of this tense · 35th percentile among 110 sector filers · read for its shareholders

From the record

ProKidney Corp.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Culleton, Bruce (Chief Executive Officer, as filed), filing under that title since 2023-12-05, 2.9 years (bottom 33% of its family); most of the 12 officers and directors filing now have filed since the record of its people begins (2022-07-13), a floor of 4.3 years the record cannot see past, so that part is not read; 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (bottom 37%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge7 in three years among 12 peoplebottom 37% of its family
  • the chief executive's years on the record2.9 yearsbottom 33% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

6.5/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed
5.1/10

How much room does it have to grow?

top 49% of 92 in its family for room to expand.

weight 33% of this tense · 51st percentile among 92 sector filers · read for itself

From the record

ProKidney Corp.'s room to grow, from the newest filed statements (fiscal 2025): cash of $109 million against no long-term debt tagged leaves 32.3% of its assets as net cash, top 46% of its family; cash from operations less capital spending is -15152.6% of revenue (bottom 6%); research spending of 12779.7% of revenue (top 6%) (its annual report).

What it rests on

  • cash less debt against assets32.3%top 46% of its family
  • cash from operations less capital spending against revenue-15152.6%bottom 6% of its family
  • research spending against revenue12779.7%top 6% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
8.8/10

What could actually drive growth from here?

top 12% of 100 in its family for growth drivers.

weight 45% of this tense · 88th percentile among 100 sector filers · read for its customers

From the record

ProKidney Corp.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 1077% (top 4%); research spending grew 11.6% a year (top 28%); capital spending grew 101.9% a year (top 4%) (its annual reports). ProKidney Corp. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • the newest year's revenue growth1077.0%top 4% of its family
  • three-year growth of research spending11.6%top 28% of its family
  • three-year growth of capital spending101.9%top 4% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate
4.0/10

Did its newest year beat what its own record pointed to?

SI estimate 4.0/10, confidence 35 of 100 (one part).

weight 22% of this tense · 40th percentile among 90 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, net income against the prior three years' average, which ranks in the bottom 40% of 90 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
one part: net income against the prior three years' average, the one part on file, ranked among 90 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: ProKidney Corp.'s expectations vs reality is put at 4.0 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the bottom 40% of 90 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton PROK · research, not advice